Samsung Bioepis and Teva (TEVA) Pharmaceutical Industries announced that the companies have entered into a license, development and commercialization agreement for EPYSQLI, Samsung Bioepis’ biosimilar to Soliris in the United States. Under the terms of the agreement, Samsung Bioepis will be responsible for the development, regulatory registration, manufacture and supply of the product, while Teva will be responsible for commercialization of the product in the U.S. The financial terms of the agreement remain confidential.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Drugmakers Raise the Prices on 583 Products to Start 2025
- Catalyst settlement with Teva a positive event, says BofA
- Catalyst Pharmaceuticals up 18% after resumption following Teva settlement
- Catalyst Pharmaceuticals reports settlement of Firdapse patent litigation with Teva
- Eton Pharmaceuticals price target raised to $18 from $15 at Craig-Hallum
Questions or Comments about the article? Write to editor@tipranks.com